Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG
Clinical Infectious Diseases · 17.04.2023 · 76 (8) · 1492-1495
DOI: 10.1093/cid/ciac949 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 15.12.2022. Verfasst von Bronwyn Bosch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Unitaid, U.S. Agency for International Development, South African Medical Research Council.
Abstract (Originalsprache)
Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
- Faculty of Medicine, Imperial College, London, United Kingdom.
Förderung
- Unitaid
- U.S. Agency for International Development
- South African Medical Research Council
- ViiV Health Care and Gilead Sciences
- National Heart, Lung and Blood Institute
- U.S. Department of Health and Human Services
- National Institutes of Health
Zitieren
APA
Bosch, B., Akpomiemie, G., Chandiwana, N., Sokhela, S., Hill, A., McCann, K., Qavi, A., Mirchandani, M., & Venter, W. D. F. (2023). Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clinical Infectious Diseases, 76(8), 1492-1495. https://doi.org/10.1093/cid/ciac949
Vancouver
Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, et al. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clinical Infectious Diseases. 2023;76(8):1492-1495. doi:10.1093/cid/ciac949
BibTeX
@article{Bosch2023,
author = {Bosch, Bronwyn and Akpomiemie, Godspower and Chandiwana, Nomathemba and Sokhela, Simiso and Hill, Andrew and McCann, Kaitlyn and Qavi, Ambar and Mirchandani, Manya and Venter, Willem Daniel Francois},
title = {Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {8},
pages = {1492--1495},
doi = {10.1093/cid/ciac949}
}
EUVIMED